Renaissance Capital logo

Hancock Jaffe Laboratories Priced, Nasdaq: HJLI

Developing bioprosthetic devices for cardiovascular surgeries.

Industry: Health Care

First Day Return: +4.8%

We are a development stage medical device company developing biologic based solutions that are designed to be life-enhancing for patients with cardiovascular disease, peripheral arterial and venous disease and end-stage renal disease (ESRD). We are currently developing three bioprosthetic implantable devices for cardiovascular disease: the Bioprosthetic Heart Valve, the Bioprosthetic Coronary Artery Bypass Graft (CoreoGraft), and the Bioprosthetic Venous Valve (VenoValve). We have previously developed and obtained FDA pre-market approval for the ProCol Vascular Bioprosthesis, a product for hemodialysis in patients with ESRD, which we sold to LMAT in March 2016; our revenue stream is derived from the sub-contract manufacturing services and royalties earned on LMAT sales pursuant to the agreement with LMAT until 2019.

Hancock Jaffe Laboratories (HJLI) Performance

Created with Highcharts 10.3.2Chart context menuHJLI vs. IPO Index (IPOUSA)Sep '18Jan '19May '19Sep '19Jan '20May '20Sep '20Jan '21May '21Sep '21Jan '22May '22Sep '22Jan '23May '23Sep '23Jan '24May '24Sep '24Jan '250%+ 100%+ 200%-100%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index